Abstract 62P
Background
Cervical intraepithelial neoplasia (CIN) is regarded as a precancerous condition of the cervix. The tumor microenvironment contains a large number of immune cells, in particular, tumor-associated neutrophils (Nph), as well as pro-inflammatory cytokines, including IL6, which causes chronic inflammation and immunosuppression. The role of IL6 in the onset and progression of CIN has been shown (Chen J, Wang L, 2022). Regulation of cytokine expression occurs at the transcriptional level, in the promoter region of the gene. For IL6, a single nucleotide polymorphism (SNP) with a substitution at position -174G→C has been described that is associated with the risk of breast cancer. IL6 polymorphism (rs2069837) is significantly associated with an increased risk of cervical cancer (Das AP, et al, 2022). However, there is no data on the involvement of SNP IL6 C-174G (rs1800795) in the occurrence and development of CIN. The aim of the study was to evaluate the role of IL6 (C-174G) polymorphism in the development of CIN.
Methods
The study included 60 patients diagnosed with high-grade squamous intraepithelial lesions (CIN II, CIN III and cancer in situ) and 30 somatically healthy women (control). The study was conducted in accordance with the requirements of the ethics commission of UlSU. The level of IL6 was determined in Nph lysate by ELISA method (Vector-Best, Russia). The presence of SNP IL6 C-174G was assessed by polymerase chain reaction with restriction enzyme analysis using RsaI endonuclease (SibEnzyme, Russia). Electrophoresis was carried out in 1.5% agarose gel. Statistical processing was carried out using Statistica 13.
Results
It was found that the -174G* allele is more common in the group with lesions of the cervix (75.7%) than in the control (53.3%). The risk of developing CIN increased with an increase in the level of IL6 in Nph with CIN (9.69 (6.89-10.85) vs 1.33 (0.78-2.25), p=0.015) and the presence of the -174G allele * (OR=0.411, 95% CI 0.220-0.768, p=0.005) (χ2=23.4, p=0.001).Simultaneous assessment of the level of IL6 in Nph and SNP IL6 C-174G allows predicting the development of CIN with sensitivity (0.769) and specificity (0.897).
Conclusions
The presence of IL6 polymorphism (C-174G) and an elevated level of IL6 in Nph indicate the possibility of CIN.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract